Best-in-RAS
Redefining what’s possible in precision oncology to treat RAS-dependent cancers
Inhibiting Active RAS
Going beyond current approaches,
we aim to inhibit the active “ON” state.
Decades of scientific research demonstrating the crucial role of RAS signaling in cancer has culminated in the opportunity to translate our knowledge into real-world solutions for patients.
We use our expert understanding of RAS signaling biology to inform rational drug design, yielding multiple approaches, including the selective inhibition of RAS-driven PI3K activation and a broad spectrum of KRAS mutants in both the “ON” and “OFF” states.